Effectiveness of Open and Robotic Prostatectomy

The investigators will follow your prostate cancer treatment outcomes and health related
quality of life following prostatectomy by asking you direct questions, collect information
from medical records and phone interviews.

Information about your prostate cancer treatment, and related health concerns, and
information regarding the cost of care, may also be collected from your medical record, other
medical center sources, and your primary care provider (PCP). Clinical information will be
collected: prior to beginning treatment (prostatectomy); 6 month, 12 months, 18 months, and
24 months after your prostatectomy; once a year thereafter for possibly up to 12 years.

You will be asked to take part in six telephone interviews regarding quality of life,
possible therapy side effects, and satisfaction with prostate cancer therapy. Each phone
interview should last 15-25 minutes. All questions are voluntary. The phone interviews will
be conducted: prior to beginning treatment (prostatectomy); 2 months, 6 months, 12 months, 18
months, and 24 months after prostatectomy; 10 additional phone interviews may be conducted
(once a year thereafter, for possibly up to 12 years).

Inclusion Criteria:

- Early stage prostate cancer (AJCC [2002] clinical stage < or = T2NXMX; T stage is
based on rectal exam findings alone).

- Gleason score based on local pathology within 12 months of registration. (Patients
with an original diagnosis of prostate cancer proceeding 12 months are also eligible
but pathology confirmation of cancer within 12 months of registration is required.)

- Serum PSA test result from within 12 months of registration

- Able to participate in baseline and follow-up phone interviews conducted in English

- Scheduled to undergo Open Radical Prostatectomy or Robotic Assisted Laparoscopic
Prostatectomy

Exclusion Criteria:

- Previous definitive primary prostate cancer therapy (prostatectomy, external
radiation, brachytherapy, cryotherapy, or other interventions)

- Previous radiation therapy to the pelvis

- Previous major reconstructive or extirpative pelvic surgery (including but not limited
to abdominal-perineal resection, or penile implant)

- Previous androgen suppression therapy (LHrH agonist or antagonist), anti-androgen
therapy (Casodex, Flutamide, or Nilandron), or estrogen therapy (DES or PC-SPEZ).
(Prior or current finasteride or dutasteride therapy is allowed)

- Known urethral stricture

- Urostomy or colostomy

- Chronic urinary catheterization